Patients Coming Off Slimming Jabs Gain Back Pounds at a Quadrupled Rate Than People Using Diet and Exercise

New research reveals that individuals who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight much more quickly than those who halt traditional lifestyle regimens.

Findings released in a major medical journal points out that while overweight individuals often shed substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.

"Individuals buying such treatments need to be cognizant of the risk of rapid weight regain when the medication concludes," stated lead investigator Dr. Susan Jebb.

That rate of regain implies a return to original weight in about one and a half years.

Analyzing Therapies

The study, which looked at dozens of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.

The team emphasize that individuals who shed pounds through diet and exercise usually have a slower creep back—perhaps 100 grams monthly—post-intervention.

Explaining the Rapid Regain

Nutrition scientists suggest the mechanism of the jabs accounts for the amplified rebound.

The injections copy a natural hormone called glucagon-like peptide-1, which controls hunger.

"Artificially providing GLP-1 levels several times higher than normal may cause the system to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.

"Discontinuation of this hormone supplement means hunger is uncontrolled, making excessive eating a significant risk."

A Lifelong Issue?

Medical guidelines recommend the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.

Professionals contend that, considering the significant potential of weight regain, the therapy is often life-long.

This opinion is reinforced by pharmaceutical companies, who note that the findings "highlight the persistent nature of excess weight," similar to managing diseases like diabetes.

User Accounts

Users who have discontinued the medication describe a intense resurgence of hunger.

"I experienced a trigger activating and I was suddenly ravenous," recalled a patient.

This difficulty is compounded if users have not developed sustainable lifestyle or habit modifications during therapy.

Widespread Interest

Figures suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.

• Use is greater among women than males.
• The 40s and 50s age group shows the highest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

Ultimately, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and lasting health benefits hinges on integrated lifestyle changes.